Cenobamate Open-Label Extension Study for YKP3089C025

Overview

About this study

The purpose of this study is to evaluate the long-term safety and tolerability of cenobamate adjunctive therapy in subjects with primary generalized tonic-clonic (PGTC) seizures who have completed the Core Study YKP3089C025.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- The subject must have successfully completed the Double-blind Treatment Period in the
Core study.

- Written informed consent signed by the subject or legal guardian, prior to entering
the study, in accordance with the International Council for Harmonisation (ICH) Good
Clinical Practice (GCP) guidelines. If the written informed consent is provided by the
legal guardian because the subject is unable to do so, a written or verbal assent from
the subject must also be obtained. As required by country-specific regulations, only
the subject may sign the ICF in accordance with ICH guidelines.

Exclusion Criteria:

- Subject tests positive, via urine drug screen at Visit 14 of the Core study, for
illicit drugs except for tetrahydrocannabinol and Cannabinoids.

- Any significant changes to the subject's medical history that, in the opinion of the
Principal Investigator, could affect the subject's safety or conduct of the study.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/3/23. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lily Wong-Kisiel, M.D.

Open for enrollment

Contact information:

Bridget Neja C.N.A.

(507) 266-9150

Neja.Bridget@mayo.edu

More information

Publications

Publications are currently not available